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Background: Insomnia and other sleep disturbances are common, persistent, and associated
with relapse in alcohol-dependent patients. The purpose of this pilot study was to compare gaba-
pentin versus placebo for the treatment of insomnia and prevention of relapse in alcohol-depen-
dent patients.
Methods: Twenty-one subjects, including 10 women who met study criteria for alcohol depen-
dence and insomnia and expressed a desire to abstain from alcohol, were recruited to the study.
During a 1 to 2 week placebo lead-in and screening phase, a complete medical history, physical
exam, blood tests, urine drug test, and structured interviews were performed to determine eligibil-
ity and patterns of alcohol use and sleep. Insomnia due to intoxication or acute withdrawal, psy-
chiatric or medical illness, medications, and other sleep disorders were ruled out. Subjects were
then randomized to either placebo (n = 11) or gabapentin (n = 10) for 6 weeks and titrated over
a 10-day period to 1,500 mg or 5 pills at bedtime. After a 4-day taper, subjects were reassessed
6 weeks after ending treatment.
Results: Gabapentin significantly delayed the onset to heavy drinking, an effect which persisted
for 6 weeks after treatment ended. Insomnia improved in both treatment groups during the medi-
cation phase, but gabapentin had no differential effects on sleep as measured by either subjective
report or polysomnography.
Conclusion: Because gabapentin is a short-acting medication that was taken only at nighttime
in this study, it may possibly exert a nocturnal effect that prevents relapse to heavy drinking by a
physiological mechanism not measured in this pilot study.
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I NSOMNIA AND OTHER sleep disturbances are com-mon, persistent, and associated with relapse in alcohol-
dependent patients (Brower, 2003; Feige et al., 2007). Among
patients admitted for alcoholism treatment, rates of insomnia
range from 36 to 91% (Brower, 2001; Cohn et al., 2003). The
duration of insomnia following alcohol withdrawal may per-
sist for 4 to 8 weeks (Alling et al.,1982) if not longer, and
sleep laboratory studies utilizing polysomnography (PSG)
suggest that sleep disturbances may persist for months to
years during sobriety (Brower, 2001). It is hypothesized that
treating sleep abnormalities in alcohol-dependent patients
with medication may decrease relapse rates, but no studies
have tested this hypothesis.
Several medications (e.g., disulfiram, naltrexone, acampro-
sate) are used to prevent relapse in alcohol-dependent
patients, but very few studies have examined their effects on
sleep (Snyder et al., 1981; Staner et al., 2006). Other medica-
tions such as trazodone and gabapentin are commonly pre-
scribed for their sleep-promoting properties (Friedmann
et al., 2003) and have shown some potential as sleep aids in
alcohol-dependent patients in open-label studies employing
subjective measures (Karam-Hage and Brower, 2000, 2003).
Yet placebo-controlled studies of these medications utilizing
objective sleep polysomnographic parameters are virtually
unknown in alcohol-dependent patients with at least one
exception (Le Bon et al., 2003). Systematically investigating
the sleep effects of medications in alcohol-dependent patients
could identify sleep-promoting, sleep-neutral, and sleep-
disruptive agents. Knowledge of these properties could then
inform clinicians about treatment options.
The purpose of this pilot study was to compare gabapentin
versus placebo for the treatment of insomnia and prevention
of relapse in alcohol-dependent patients. Gabapentin was
chosen for a number of reasons. Open-label studies have
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demonstrated that gabapentin-treated patients with alcohol
dependence and insomnia report readily measured improve-
ment in sleep over time (Karam-Hage and Brower, 2000,
2003). Moreover, gabapentin-treated alcohol-dependent
patients with insomnia were less likely to feel tired and worn
out upon awakening than were trazodone-treated
alcohol-dependent patients (Karam-Hage and Brower, 2003).
In addition, gabapentin has been shown to improve sleep as
measured by PSG, especially slow wave (deep) sleep, in
healthy control subjects (Bazil et al., 2005; Foldvary-Schaefer
et al., 2002; Rao et al., 1988), in patients with epilepsy (Legros
and Bazil, 2003), and in patients with restless legs syndrome
(Garcia-Borreguero et al., 2002). Its putative actions of
enhancing GABA and modulating glutamate systems in the
brain are consistent with its sleep-promoting effects (Dooley
et al., 2007; Kuzniecky et al., 2002). Finally, it is well-tolerated
in the presence of alcohol by healthy subjects, heavy drinkers,
and alcoholics (Bazil et al., 2005; Bisaga and Evans, 2006;
Myrick et al., 2007) and in patients undergoing treatment for
alcohol withdrawal (Bonnet et al., 2003, 2007; Mariani et al.,
2006; Voris et al., 2003). Subjects were selected for their com-
plaints of insomnia that persisted following the period of acute
alcohol withdrawal. Validated subjective and objective
measures were used to measure both sleep and drinking
parameters. The study hypotheses were as follows: (1)
gabapentin would improve drinking outcomes compared to
placebo during the 6-week medication phase, (2) gabapentin
would improve symptoms of insomnia compared to placebo
during the 6-week medication phase, (3) improvement in
drinking outcomes would be associated with improvement in
insomnia, and (4) beneficial effects of gabapentin would be
sustainable for the 6-week postmedication follow-up period.
MATERIALS AND METHODS
Subjects
Twenty-one subjects, including 10 women, were recruited from
either an outpatient alcohol treatment center after reviewing medical
records or from the surrounding community by advertisement. The
study protocol and recruitment procedures were approved by the
Institutional Review Board. Consent was obtained to perform a
breath alcohol test, and written informed consent for the full proto-
col was obtained if the blood alcohol level was <0.05% as measured
by breathalyzer.
Subjects 18 years and older were eligible if they (1) met DSM-IV
criteria (American Psychiatric Association, 2000) for current alcohol
dependence, (2) met study criteria for insomnia, defined as ongoing
complaints of difficulty falling asleep or staying asleep, waking too
early, or not feeling rested in the morning that had lasted for at least
6 months prior to the screening interview and caused significant dis-
tress or daytime impairment, and (3) expressed a desire or willingness
to abstain from alcohol and other drugs (except nicotine) during the
study. Women were eligible only if they were not nursing, tested neg-
ative for pregnancy, and used reliable contraception if pregnancy was
possible. Insomnia was evaluated and diagnosed by one of the
authors (KB, SS) via the Insomnia Interview Schedule (Morin, 1993)
at a mean of 11.2 (3.0) days prior to overnight PSG. The Insomnia
Interview Schedule does not require parameters such as sleep onset
latency or time spent awake at night to exceed threshold values so as
to diagnose insomnia.
Subjects were excluded if insomnia was due to medications or
the subject required treatment with medications known to affect
sleep (e.g., sedating antidepressants, anticonvulsants, antipsychotic
agents, centrally acting antihistamines or antihypertensives, oral
corticosteroids, sedative-hypnotics, psychomotor stimulants, or
theophylline). Subjects taking medications known to influence
drinking outcomes such as naltrexone, disulfiram, or acamprosate
were also excluded. Subjects taking nonsedating antidepressants at
a stable dose for the past 2 months with no anticipated change in
dose during the course of the study were not necessarily excluded,
unless the investigator determined that either the medication or
the disorder for which it was prescribed was contributing to their
insomnia. Three subjects qualified by taking stable doses of cita-
lopram 20 mg ⁄d, fluoxetine 40 mg ⁄d, or sertraline 100 mg ⁄d for
at least 2 months prior to study entry. Subjects were excluded if
their insomnia was due to medical illness, chronic pain, a nonal-
cohol substance use disorder (except nicotine dependence), or
DSM-IV panic disorder, social phobia, generalized anxiety disor-
der, posttraumatic stress disorder, major depression, anorexia
nervosa, or bulimia nervosa in the past month. A lifetime history
of psychosis, bipolar disorder, or obsessive-compulsive disorder
was also the cause for exclusion. Blood tests to rule out medical
illness included electrolytes, glucose, thyroid stimulating hormone,
renal function tests, and liver function tests.
To exclude the possibility of insomnia due to acute effects of alco-
hol intoxication and withdrawal, insomnia had to persist during the
placebo lead-in period for at least 1 week of abstinence in the absence
of withdrawal symptoms as determined by a structured withdrawal
rating scale (CIWA-Ar < 8) (Sullivan et al., 1989). Other exclusion-
ary criteria included danger to self or others, unstable or distant
housing, illiteracy, cognitive impairment (Mini-Mental State
Exam < 27; Folstein et al., 1975), personality disorders judged likely
to interfere with compliance, known allergy or hypersensitivity to
gabapentin, and impaired renal function (blood urea nitrogen or cre-
atinine >1.5 times normal). Subjects were also excluded if their first
night of PSG revealed evidence of a primary sleep disorder including
sleep apnea (respiratory distress index >10) or periodic leg move-
ment (PLM) disorder (PLM index with arousals >15).
Of 35 participants who underwent in-person screening and met
study criteria for insomnia, 14 were excluded: 7 were lost to follow-
up before completion of screening, 1 did not meet alcohol depen-
dence criteria, 1 was referred for residential treatment, 1 was unable
to abstain from alcohol during the screening period, 2 had positive
urine drug screens for cocaine, and 2 had PSG-confirmed sleep disor-
ders (1 with sleep apnea, 1 with PLM disorder).
Procedures
The study design consisted of (1) a screening phase of 1 to 2 weeks,
including a single-blind placebo lead-in period and overnight PSG,
(2) a 6-week randomized double-blind, parallel-group trial of gaba-
pentin versus placebo, and (3) a 6-week posttrial follow-up visit.
During screening, a complete medical history, physical exam, blood
tests, and urine drug test were performed as well as interviews and
questionnaires to determine patterns of alcohol use, sleep, craving,
and mental status. During this phase, subjects were instructed to fol-
low their usual sleep schedule and to keep a sleep diary to record
the pattern of their sleep schedule prior to PSG. After completing
the screening phase, qualified subjects (n = 21 including 10 women)
were randomized to either placebo (n = 11) or gabapentin
(n = 10) for 6 weeks, balanced for gender (Stout et al., 1994). The
randomization schedule was generated by a statistician and imple-
mented by a nonblinded research pharmacist. Study investigators,
raters, and subjects were blinded to treatment assignment until all
study visits were completed and the dataset was cleaned and locked.
Subjects were assessed in-person at screening, baseline, and weeks 1,
2, 3, 4, 6, 7, 9, and 12.
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During the double-blind phase, study medication was titrated to 5
capsules of either gabapentin or placebo orally 45 minutes prior to
bedtime over a 10-day period as tolerated. Each capsule received by
the active medication group contained 300 mg of gabapentin for a
final target dose of 1,500 mg prior to bedtime. Subjects received 1
capsule at bedtime for 2 nights, then 2 capsules for 2 nights, and
finally 3 capsules for 3 nights. On day 8, subjects were reassessed by
the study physician or nurse practitioner who increased the dose as
tolerated to 4 capsules at bedtime for 2 nights, and then to the final
dosage of 5 capsules at bedtime. Gabapentin and placebo capsules
were identical in appearance and dispensed from visit to visit. After
6 weeks the medication was tapered over 4 days. Subjects also
received up to six 30-minute sessions of behavioral therapy as out-
lined in a treatment manual with a focus to enhance adherence to
study medication (Carroll and O’Malley, 1996). Behavioral therapy
did not focus on sleep issues. Subjects were paid for participating in
the study using a schedule that provided payments of $50 each upon
completing visits at baseline and on weeks 3, 6, and 12; as well as $25
each for completing visits on weeks 1, 2, 4, 7, and 9, for a total possi-
ble compensation of $325.
Measures
Drinking and Other Substance Use. The Time-Line Follow-
Back Interview (TLFB) (Sobell et al., 1988) was used to measure the
frequency and quantity of self-reported drinking during both the
90 days prior to baseline and the 12-week study period. Collateral
corroboration of drinking was obtained at baseline and Week 6. Bio-
chemical corroboration of self-reported drinking consisted of breath
tests for alcohol at each study visit, and a blood level for gamma-
glutamyl transferase (GGT) at baseline and 6 weeks. A urine drug
screen tested for amphetamines, barbiturates, cannabinoids, ben-
zodiazepines, cocaine, and opioids. Severity of craving was measured
by the Obsessive Compulsive Drinking Scale (Anton et al., 1996;
Moak et al., 1998). Consequences of drinking were measured with
the Short Index of Problems (Feinn et al., 2003; Miller et al., 1995).
Tobacco use was compared between groups by dichotomizing sub-
jects into smokers and nonsmokers, and averaging the number of cig-
arettes smoked per day as determined by the TLFB.
Subjective Sleep. The 4-item self-administered Sleep Problems
Questionnaire (SPQ) (Jenkins et al., 1988) was selected for its respon-
siveness to improvement in sleep over 4 to 6 week intervals in alco-
hol-dependent patients (Karam-Hage and Brower, 2000, 2003). The
4 items ask ‘‘How often in the past month did you: (1) Have trouble
falling asleep? (2) Wake up several times per night? (3) Have trouble
staying asleep (including waking far too early)? (4) Wake up after
your usual amount of sleep feeling tired and worn out?’’ Each of the
4 questions is self-rated on a scale of 0 to 5 for a maximum score of
20, with responses coded as follows: ‘‘Not at all’’ = 0, ‘‘1 to
3 days’’ = 1, ‘‘4 to 7 days’’ = 2, ‘‘8 to 14 days’’ = 3, ‘‘15 to
21 days’’ = 4, and ‘‘22 to 31 days’’ = 5. Thus, the SPQ measures
insomnia as a construct by tapping into the 4 most likely complaints
of patients during a clinical encounter: early, middle and late insom-
nia, and sleep that is not refreshing. These complaints also corre-
spond to the ‘‘Insomnia Type’’ of substance-induced sleep disorder in
the DSM-IV (American Psychiatric Association, 2000). In addition,
subjects completed sleep diaries on a daily basis during the medica-
tion phases (placebo lead-in and gabapentin vs. placebo), yielding
weekly means for sleep onset latency (SOL), sleep efficiency (SE),
wake time after sleep onset (WASO), and total sleep time (TST)
(Conroy et al., 2006).
Objective Sleep. Overnight PSG was performed in the sleep lab-
oratory on 3 occasions. Two consecutive nights occurred at the end
of the placebo lead-in period. The first night served as laboratory
adaptation and screening for primary sleep disorders (e.g., sleep
apnea). The second night served as the baseline recording prior to the
double-blind phase. The third night occurred after 3 weeks on study
medication, to compare early effects of gabapentin versus placebo on
objective sleep parameters. Subjects were scheduled to arrive at the
University of Michigan General Clinical Research Center at
20:00 hours and had electrodes attached at 20:30 hours. Lights were
typically out by 23:00 hours and on again at 07:00 hours the next
morning. PSG included an electroencephalogram (C3 ⁄A2 EEG); ref-
erential electro-oculogram with electrodes placed at the outer canthus
of each eye, one immediately above the other just below the horizon-
tal plane, to record both horizontal and vertical slow and rapid eye
movements (REMs); submental electromyogram (EMG); respiratory
monitoring (nasal-oral thermistor monitor, abdominal and chest
monitors, and ear or finger oximetry); electrocardiogram; and EMG
of the anterior tibialis muscle of each leg to document PLMs. Data
were recorded digitally using a paperless system (Telefactor Corp.,
West Conshohocken, PA) and visually scored from the digital images
using standard criteria (Rechtschaffen and Kales, 1968). All records
were scored by a single registered PSG technician, whose inter-rater
reliability results were over 90% in our internal tests. After scoring,
each PSG recording was interpreted by one of the authors (FC) who
was blind to study medication group and clinical history except for
age and gender. PSG parameters included TST, SOL, WASO, SE,
the percentage of time spent in sleep Stages 1 (S1%), 2 (S2%), slow
wave sleep (SWS%) and REM sleep, and REM onset latency
(REML) using standard criteria (Rechtschaffen and Kales, 1968).
Other. The Structured Clinical Interview for DSM-IV Diagnoses
(First et al., 1997) was administered by trained psychiatric nurses,
and used to confirm a diagnosis of current alcohol dependence
(Kranzler et al., 1996b) and to rule out exclusionary DSM-IV diag-
noses as listed above. Severity of anxiety and depressive symptoms
was measured with the 17-item Structured Interview Guide for the
Hamilton Depression Rating Scale (Williams, 1988) and the Hamil-
ton Anxiety Rating Scale (Hamilton, 1959). Compliance with study
medication was measured in all subjects using electronic pill bottle
caps (MEMS TrackCap system; Aprex Corp, Fremont, CA) that
recorded each time the bottle was opened (Cramer et al., 1989). At
each study visit, the computerized report of opening times was recon-
ciled with pill counts and the patient’s self-report (Matsuyama et al.,
1993). Blood levels of gabapentin were used as a secondary measure
of compliance. Concomitant treatment, including attendance at
meetings of Alcoholics Anonymous, was measured with the Project
MATCH Form 90 (Miller, 1996).
Analyses
Preliminary analyses were conducted to examine the distribution
of variables and to compare the gabapentin and placebo groups at
baseline on demographic, substance use, sleep, and psychiatric vari-
ables. Because of small sample sizes and nonnormal distributions,
continuous variables were analyzed with nonparametric statistics,
and each continuous variable is represented by its median (Md) and
interquartile range (IQR). An exception is data on dosage where full
ranges are reported.
The primary drinking outcome variable was survival in days to
first episode of heavy drinking. Heavy drinking was defined as
more than 4 standard drinks in a day for women and more than
5 standard drinks in a day for men, or presenting to any study
visit with a blood alcohol level >0.08% as measured by breatha-
lyzer. An intention-to-treat analysis was used, and any subjects
lost to follow-up were categorized as relapsed to heavy drinking
at the time of their last assessment. Collateral corroboration of
self-reported drinking was obtained on 13 of 14 subjects who
remained in the study at the 6-week follow-up. In no cases did
the collateral informant report heavy drinking when the subject
did not. The distribution of relapse to heavy drinking was
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compared using Kaplan–Meier survival curves and log-rank tests.
Separate analyses were conducted for 6 and 12 weeks to deter-
mine if potential treatment effects persisted. A Cox regression
analysis was used to control for baseline variables that correlated
with time to heavy drinking in preliminary analyses. A secondary
drinking outcome variable was complete abstinence from drinking
alcohol during the 6-week trial.
The primary sleep variable of interest was improvement in the
Sleep Problems Questionnaire (SPQ) score at 6 and 12 weeks,
because of its significance in open label pilot studies (Karam-Hage
and Brower, 2000, 2003). Differences in sleep outcomes were com-
pared between treatment groups, and then used to predict heavy
drinking outcomes at Week 6. Sleep diary and polysomnographic
sleep variables were analyzed as secondary sleep outcomes. All tests
were 2-tailed and judged significant if p < 0.05.
RESULTS
Baseline Characteristics and Correlations With Drinking
Outcomes
No significant baseline differences between groups were
observed on demographic, drinking, sleep, and psychiatric
measures (Tables 1 and 2). Significant correlations between
baseline characteristics and time to first heavy drinking day at
12 weeks were found for age (Spearman’s r = 0.44,
p < 0.05) and education (Spearman’s r = 0.50, p = 0.02).
Because age and education were moderately correlated with
each other (Spearman’s r = 0.53, p = 0.01), only education
was entered into the Cox regression analysis in addition to
treatment group so as to limit the number of covariates given
the small sample size. Results from the primary comparisons
between the 2 medication groups did not change when
adjusted for age, instead of education.
Drinking Outcomes by Treatment Group at 6 and
12 Weeks
Drinking outcomes during the first 6 weeks could not be
verified for 6 of the 7 noncompleters (2 in the gabapentin
group and 4 in the placebo group), so they were conserva-
tively classified as heavy drinkers. Drinking data for the
remaining noncompleter (on placebo) was obtained by a tele-
phone interview which confirmed heavy drinking. Altogether,
among the gabapentin group, 3 (30.0%) of 10 were catego-
rized as having relapsed to heavy drinking during the 6-week
trial versus 9 (81.8%) of 11 in the placebo group (Fisher’s
exact test, p = 0.03). A survival analysis of time to heavy
drinking by treatment group revealed a statistically significant
difference (log rank p = 0.03) favoring the gabapentin group
(Fig. 1). After adjusting for education, the relative risk (RR)
of relapse to heavy drinking in the gabapentin group was sig-
nificantly lower than that of placebo group (Cox regression,
RR = 0.25, p = 0.047). Additionally adjusting for the base-
line percentage of heavy drinking days in the 6 weeks prior to
screening did not change the result. Results were similar
among the 14 completers.
Of the 14 patients who completed the 6-week data collec-
tion, 12 (86%) patients were followed until Week 12. The 2
patients lost to follow-up during this interval were assumed to
have relapsed to heavy drinking. Using an intention-to-treat
Table 1. Baseline Characteristics by Treatment Groupa
Variablesb Gabapentin (n = 10) Placebo (n = 11)
Age (year) 46.0 (30.8–60.0) 44.0 (41.0–54.0)
Education (year) 14.0 (12.0–18.0) 14.0 (12.0–15.0)
Male 6 of 10 (60.0%) 5 of 11 (45.5%)
Ethnicity
White 9 of 10 (90.0%) 7 of 11 (63.6%)
Black 1 of 10 (10.0%) 1 of 11 (9.1%)
Hispanic 0 2 of 11 (18.2%)
Other 0 1 of 11 (9.1%)
Employed 6 of 10(60.0%) 8 of 11 (72.7%)
Marital status
Married 6 of 10 (60.0%) 2 of 11 (18.2%)
Divorced 2 of 10 (20.0%) 6 of 11 (54.5%)
Other 2 of 10 (20.0%) 3 of 11 (27.3%)
Lives alone 1 of 9 (11.1%) 3 of 11 (27.3%)
% Drinking days in past 42 days 94.0 (58.9–100.0) 92.9 (52.4–100.0)
Drinks ⁄ drinking day in past 42 days 4.3 (3.3–12.0) 7.7 (4.8–10.6)
% Heavy drinking days in past 42 days 16.7 (3.0–70.2) 54.8 (21.4–90.5)
Obsessive Compulsive Drinking Scale 9.0 (5.75–20.5) 12.0 (6.0–14.0)
Short Inventory of Problems 19.0 (7.3–35.3) 30.0 (20.0–38.0)
Age at onset of problem drinking (yr) 24.5 (20.0–34.8) 24.0 (21.0–36.0)
Family history positivec 6 of 10 (60.0%) 8 of 11 (72.7%)
Gamma-glutamyl transferase [GGT] 43.0 (37.8–90.5) 50.0 (22.3–170.5)
Current tobacco smoker 6 of 10 (60.0%) 3 of 11 (27.3%)
Cigarettes ⁄ day [#] 12.4 (0.0–22.5) 0.0 (0.0–2.0)
Hamilton Depression Rating 6.0 (3.8–8.5) 8.0 (6.0–11.0)
Scale Hamilton Anxiety Rating Scale 7.5 (3.8–9.8) 8.0 (6.0–12.0)
aAll comparisons between treatment groups were not significant using Mann–Whitney U-tests for continuous variables and either chi square or Fisher’s exact tests
for categorical variables. Medians (interquartile ranges) are shown for continuous variables and frequencies (percentages) for discrete variables.
bVariables organized by demographic, substance-related, and psychiatric domains.
cPositive family history for alcohol problems in any first-degree relative by subjects’ self-report.
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analysis, 6 (60%) of 10 subjects in the gabapentin group
relapsed to heavy drinking by 12 weeks versus 11 (100%) of
11 in the placebo group (Fisher’s exact test, p = 0.04).
Extending the survival analysis from baseline to 12 weeks also
revealed a statistically significant difference (log rank
p = 0.003) favoring the gabapentin group (Fig. 1).
Although continuous abstinence through 6 weeks was
more common in the gabapentin versus placebo group, the
difference was not statistically significant using an intention-
to-treat analysis. Altogether, 4 (19.0%) of 21 subjects
abstained from alcohol during the 6-week trial, including 3
(30%) of 10 subjects in the gabapentin group and 1 (9.1%) of
11 subjects in the placebo group (Fisher’s exact test,
p = 0.31). Only 1 (4.8%) of 21 subjects remained continu-
ously abstinent for 12 weeks.
Sleep Outcomes by Treatment Group
SPQ scores were available for 14 subjects at 6 weeks and
11 subjects at 12 weeks. To conduct an intention-to-treat
analysis, the patients lost to follow-up by 6 weeks were
assumed to have no improvement in sleep (i.e., zero change
scores). Treatment group did not predict SPQ change scores
from baseline to 6 weeks in either the intention-to-treat
(n = 21) or completer (n = 14) analyses. In the intention-
to-treat group, for example, the Md (IQR) change scores for
the gabapentin and placebo groups were 5.5 (0 to 10.2) and
0 (0 to 7.0), respectively [U = 46.5, Z = )0.62, p = 0.53,
effect size (ES) = 0.14]. Overall, the SPQ score improved
significantly from baseline to 6 weeks in the 14 patients who
completed both assessments by a Md (IQR) of 7 (0.8 to
11.8) points (Wilcoxon signed rank test for related samples:
Z = )2.91, p = 0.004; ES = 0.55). Between 6 and
12 weeks there was no overall change in SPQ scores
(n = 11), however the difference between groups at
12 weeks showed a non-significant trend with a moderate
ES, (U = 4.5, Z = )1.80, p = 0.07, ES = 0.54), because
of worsened sleep in the gabapentin group and improved
sleep in the placebo group (Table 2).
Sleep diary parameters (TST, SOL, SE, and WASO) were
recorded and averaged over 1-week intervals prior to baseline,
3, 6, and 12 weeks (Table 2). To parallel the SPQ analysis
during the medication phase, we tested for significant differ-
ences between treatment groups in change scores from base-
line to 6 weeks (n = 14). Using Mann–Whitney U tests, none
of these differences was significant. The largest ES was
observed with SOL and paradoxically favored the placebo
group compared to the gabapentin group (U = 16.0,
Z = )1.0, p = 0.30, ES = 0.28).
PSG parameters were recorded in 20 subjects at baseline
(Table 2). Only one difference between groups approached
significance: a more prolonged REM sleep latency was
observed in the placebo group (U = 24, Z = )1.97,
p = 0.052, ES = 0.49). PSG parameters were recorded in 16
subjects at both baseline and 3 weeks (Table 2). Using a series
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found for change over time on any of the 9 PSG parameters,
with all ES < 0.30. Moreover, treatment group did not pre-
dict changes in PSG-measured TST, SOL, SE, WASO, S1%,
S2%, SWS%, REM%, or REML. The largest ES in these
latter analyses was seen for SOL, because the gabapentin
group paradoxically worsened over 3 weeks compared to the
placebo group (U = 19, Z = )1.37, p = 0.17, ES = 0.34).
Sleep Improvement and Drinking Outcomes
A significant relationship between sleep improvement and
good drinking outcomes during the first 6 weeks was found
for the 14 participants who completed the medication trial.
The group that did not relapse (n = 9) had higher SPQ
change scores than those that did relapse (Md = 9.0,
IQR = 5.5–15.0 vs. Md = 1.0, IQR = )0.5–4.0; U = 5.0,
Z = )2.34, p = 0.019, ES = 0.63).
Indicators of Study Validity
Attrition. Seven (33%) of 21 subjects either withdrew
from the study or were lost to follow-up during the 6-week
trial phase, including 2 (20%) of 10 of the gabapentin group
and 5 (45%) of 11 of the placebo group (Fisher’s exact test,
p = 0.36). This rate of attrition was similar to other clinical
trials with alcohol-dependent subjects (Kranzler et al., 1996a).
Dosing. Altogether (n = 21), the gabapentin group took
medication over a median duration of 42 (31 to 42) days
versus 39 (22 to 41) days for the placebo group (U = 30.5,
Z = )1.75, p = 0.08, ES = 0.38). Treatment groups did
not differ significantly in terms of the prescribed dose among
subjects still taking medication during Week 6 of the trial
(n = 14). The overall median number of pills across both
groups at Week 6 was 5.0 pills nightly. The range of average
nightly dosing during Week 6 for the gabapentin and placebo
groups was 4.1 to 5.0 pills (1,218 to 1,500 mg) and 3.4 to 5.0
pills, respectively.
Medication Adherence. Subjects were assessed as 100%
adherent with medication if they opened their pill bottle once
per night for 42 nights at approximately bedtime, and
returned the correct number of fewer pills for each opening.
Any deviations from this criterion (e.g., more or less openings
than expected, and taking fewer or extra doses than pre-
scribed) were discussed during compliance enhancement ther-
apy. The following summary statistic was computed for
adherence: (1) Adherence with number of doses = (# of days
that doses were verified by both MEMS cap openings and pill
counts ⁄42 days) · 100%. Across all 21 subjects, 72.7% of
doses were taken, including 69.0% of doses in the placebo
group and 76.7% in the gabapentin group. Among the 14
subjects who completed the 6-week trial, 94.4% of doses were
taken. No significant differences in adherence were found
between treatment groups.
Gabapentin blood levels were drawn at Week 6 and
were available for 11 of 14 subjects that completed Week
6. Expected values range from 2.0 to 12.0 lg ⁄ml (Mayo
Medical Laboratories, Rochester, MN). The 5 subjects in
the placebo group all had values of 0 except for 1 subject
with 0.6 lg ⁄ml, which is unexplained although the limit of
quantification for the assay was 0.5 lg ⁄ml. (After reviewing
Fig. 1. Intention-to-treat (n = 21) Kaplan–Meier survival curves illustrating time to first day of heavy drinking from baseline to the end of both the medica-
tion trial at 42 days and the 6-week posttreatment follow-up phase at 84 days. Log-rank tests of differences between treatment groups (gabapentin vs. pla-
cebo) at both 6 and 12 weeks were statistically significant (p = 0.03 and p = 0.003, respectively).
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the source file of progress notes that were completed by
the research therapist after each study visit, we concluded
that actual gabapentin ingestion by this subject was highly
unlikely.) The 6 subjects randomized to gabapentin all had
values ranging from 2.4 to 7.1 lg ⁄ml, except for 1 subject
with a value of 0. Interestingly, this 1 subject relapsed to
heavy drinking by 6 weeks.
Study Blind. Neither subjects nor investigators accurately
predicted at the end of Week 6 which study medication the
subject received, confirming the integrity of the double blind
for the 13 subjects who had these data collected. Among sub-
jects, 7 (54%) of 13 were correct about which study medica-
tion they took, including 3 (50%) of 6 in the placebo group
and 4 (57%) of 7 in the gabapentin group. The investigators
were also correct in only 7 (54%) of 13 cases.
Biochemical Corroboration of Self-Reported Drinking.
The statistic, average drinks per day, was calculated as the
total number of standard drinks reported during an interval
of time divided by the number of days in that interval. Blood
levels of GGT correlated with average drinks per day for the
6-week period both before (n = 20, Spearman’s r = 0.54,
p = 0.014) and after baseline (n = 13, Spearman’s r = 0.61,
p = 0.03). The average decrease in GGT blood levels from
baseline to 6 weeks correlated moderately but nonsignifi-
cantly with the decrease in average drinks per day from
baseline to 6 weeks for the 12 subjects who had data at both
time points (Spearman’s r = 0.44, p < 0.15). Thus, the
GGT scores were consistent with levels of self-reported
drinking.
Concomitant Treatment. No significant differences
between treatment groups were found for concomitant inter-
ventions such as the number of Alcoholic Anonymous meet-
ings attended.
Adverse Events
A total of 38 adverse events among 20 subjects were
reported as either possibly or probably related to study medi-
cation (18 events for 10 placebo subjects and 20 events for 10
gabapentin subjects). The other 1 subject from the placebo
group was lost to follow-up before the first follow-up visit.
The most common side effects attributed to gabapentin versus
placebo, respectively, were somnolence (3 subjects vs. 1 sub-
ject), headache (3 subjects in each group), dizziness (2 subjects
vs. 1 subject), indigestion (2 vs. 4 subjects), nerve or muscle
pain (2 subjects vs. none) and altered mental state such as feel-
ing ‘‘spacey’’ or ‘‘fuzzy’’ (0 vs. 2 subjects). Three side effects
occurred in 1 subject per group: tingling in hands, memory
disturbance, and ataxia. In addition, several reported side
effects each occurred in 1 gabapentin-treated subject versus
no placebo subjects: dry mouth, menstrual cramps, diarrhea,
constipation, muscle twitching, and paleness. Altogether 6
events, including 4 in the gabapentin group, were rated as
moderate or severe; all others were rated mild. Adverse events
resulted in changing the dose of medication for 1 subject
receiving placebo and 3 subjects receiving gabapentin. In no
cases did adverse events cause discontinuation of medication,
although this information was not known for the 6 subjects
that were lost to follow-up. No serious adverse events
occurred.
DISCUSSION
Prior to any discussion of major findings and their potential
importance, it is necessary to caution the reader that this was
a pilot study with a small sample size, so the findings must be
considered preliminary. That said, the major finding of this
pilot study was that bedtime administration of gabapentin
significantly delayed the onset of relapse (defined as the dura-
tion of time to the first heavy drinking episode) in alcohol-
dependent patients selected for clinical insomnia at both 6
and 12 weeks. Complete and continuous abstinence from any
drinking was not associated with treatment group, but the
proportion of subjects that relapsed to heavy drinking was
smaller in the gabapentin versus placebo group at both 6 and
12 weeks. Thus, gabapentin had a positive effect on relapse
prevention during the 6 weeks of its administration, which
persisted for another 6 weeks after its treatment ended.
A second important finding was that all subjects reported
improved sleep during the 6-week trial. Contrary to expecta-
tion, gabapentin did not improve SPQ sleep scores any more
than placebo did during the 6 weeks of its administration.
Moreover, PSG-measured sleep parameters did not show
improvement from baseline to 3 weeks in either treatment
group. SWS or delta sleep describes the stages of sleep (Stages
3 and 4 combined) that characterize the deepest and poten-
tially most refreshing sleep. Although gabapentin may
increase SWS% in some populations (Bazil et al., 2005; Fold-
vary-Schaefer et al., 2002; Garcia-Borreguero et al., 2002;
Legros and Bazil, 2003; Rao et al., 1988) during equivalent
time frames, it had no significant effect on SWS% in this
short-term pilot study of alcohol-dependent individuals with
insomnia.
One difference in sleep between the 2 treatment groups,
although not significant (p = 0.07), was notable because of
its moderate ES (0.54). After discontinuation of study medica-
tion, the gabapentin group had worse sleep (PSG scores) than
the placebo group. The relative worsening of sleep after
stopping gabapentin is suggestive of either withdrawal or a
return to insomnia. Insomnia has been described in 1 case
series as a gabapentin-related withdrawal symptom (Cora-Lo-
catelli et al., 1998) and also in an 81-year-old patient after a
1-week gabapentin taper (Tran et al., 2005), but 6 weeks of
persisting insomnia as a withdrawal symptom from gabapen-
tin has not been reported previously (Norton, 2001). Thus, a
return to co-occurring insomnia seems more likely as an
explanation.
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The last major finding was that the participants who
relapsed to heavy drinking during the 6-week trial had less
improvement in insomnia than those who did not. This was
an association and no inferences about causation can be
made. Moreover, we did not find evidence that gabapentin’s
positive effect on preventing relapse was mediated by its
effects on sleep, as placebo-treated subjects also had improved
sleep. Nevertheless, gabapentin, which is short-acting and
administered 3 to 4 times daily to treat epilepsy and neuro-
pathic pain, was taken in this pilot study only at bedtime. Effi-
cacy with once nightly administration is a practical advantage,
because somnolence is a common side effect of gabapentin as
it was in this study (Beydoun et al., 1995). Efficacy with once
nightly administration may also have theoretical implications;
because the mechanism by which gabapentin prevented
relapse began during the nighttime without an obvious effect
on sleep and then persisted during the day. This suggests some
longer-acting neuromodulator effect, rather than a shorter-
acting effect on sleep. In other words, gabapentin may exert a
nocturnal effect that improves drinking outcomes via a physi-
ological mechanism not measured in this pilot study.
A discrepancy between subjective and objective sleep results
deserves mention. At baseline both treatment groups overesti-
mated SOL and underestimated WASO compared to PSG
values (Table 2). A similar discrepancy was noted by Currie
et al., 2004b) and was predictive of relapse in our sample inde-
pendent of treatment group (Conroy et al., 2006). The lack of
differential improvement between treatment groups in PSG-
recorded WASO during the first 6 weeks may reflect the
short-acting nature of gabapentin, resulting in minimal
impact on nocturnal awakenings.
Gabapentin comprises a new class of medications that
includes pregabalin and blocks voltage-dependent calcium
channels by binding to its alpha-2-delta subunit (Stahl, 2004).
It also increases cerebral GABA levels (Kuzniecky et al.,
2002) and may modulate the release of glutamate and norepi-
nephrine (Dooley et al., 2007). These effects might explain its
potential to improve sleep and reduce anxiety in other studies
(Foldvary-Schaefer et al., 2002; Pande et al., 1999, 2000) and
to prevent relapse in this pilot study.
This is the first controlled trial to investigate the efficacy of
gabapentin to improve sleep in alcohol-dependent patients. It
is also the first controlled study to investigate gabapentin’s
efficacy to prevent relapse to heavy drinking after the acute
alcohol withdrawal phase has passed. By contrast, studies of
gabapentin to treat acute alcohol withdrawal reveal mixed
results (Bonnet et al., 2003, 2007; Mariani et al., 2006; Voris
et al., 2003) The potential efficacy of gabapentin to prevent
relapse is particularly notable because it has low addictive
potential [with some recently reported exceptions (Pittenger
and Desan, 2007; Victorri-Vigneau et al., 2007)], does not
undergo hepatic metabolism and has few interactions with
other medications (Beydoun et al., 1995), is relatively safe
when combined with alcohol (Bazil et al., 2005; Bisaga and
Evans, 2006; Myrick et al., 2007), and is not associated with
fatal overdoses when taken alone (Klein-Schwartz et al.,
2003). Gabapentin was also safe and well-tolerated in this
study.
Strengths of this randomized trial included its placebo-con-
trolled, double-blind study design, strict selection criteria to
rule out comorbid conditions affecting sleep, standardized
characterization of subjects across a variety of sleep and
drinking variables, and intention-to-treat analyses. In addi-
tion, adherence to study medication was measured by multi-
ple methods, biochemical corroboration of self-reported
alcohol use was obtained, integrity of the study blind was
maintained, and both subjective and objective sleep measures
were obtained.
The major limitation of this pilot study was its small sample
size which may have prevented detecting differences between
treatment groups. Funding restraints prevented recruitment
of a larger sample. Generalizing the results to other alcohol-
dependent patients, therefore, is very limited, both because of
the small sample size and the strict selection criteria that were
utilized. Whether gabapentin also prevents relapse to heavy
drinking in alcohol-dependent patients without insomnia is
unknown. All subjects in this study had insomnia. In addi-
tion, the large number of statistical tests that we conducted
increased the risk of a Type I error, so that positive results
may also be questioned. Nevertheless, the main positive result
—increased time to relapse in the gabapentin group—was a
primary outcome variable chosen a priori. The high attrition
rate (7 of 21 subjects at 6 weeks) was another study limita-
tion, even though it was comparable to rates observed in
other clinical trials with alcohol-dependent subjects (Kranzler
et al., 1996a). The schedule of subject payments for which
$150 of the total reimbursement ($325) could be obtained by
week 3 of the study may have contributed to attrition at 6
and 12 weeks. In other words, subjects could obtain $150 dur-
ing the first 3 weeks, but only a total of $175 during the next
9 weeks. Finally, subjects were allowed to sleep according to
their usual schedules at home, so as to learn about the pat-
terns of their sleep disturbance. A limitation of this methodol-
ogy, however, is that some subjects manifested an irregular
sleep schedule prior to their sleep laboratory studies, and this
may have affected the results of their nocturnal PSG record-
ings. In particular, group effects could have been either ampli-
fied or diminished, particularly given the small sample size.
Consequently, differential improvements in PSG parameters
may have been obscured leading to false negative results.
Irregular sleep patterns were not unexpected because poor
sleep hygiene in alcohol-dependent patients has been previ-
ously reported (Currie et al., 2003).
Future studies should employ larger sample sizes and
examine the efficacy of gabapentin for relapse prevention in
the absence of insomnia, determine optimal dosing, monitor
subjects for longer periods of time, and assess for discontinua-
tion syndromes. Testing gabapentin alone and in combination
with cognitive-behavioral therapy for insomnia will also be
important, given the early successes of the latter in treating
alcohol-dependent subjects (Arnedt et al., 2007; Currie et al.,
2004a). In addition, investigating gabapentin’s effects on
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mechanisms such as hyperarousal of the central nervous sys-
tem (Feige et al., 2007), homeostatic sleep drive impairment
(Irwin et al., 2002), and circadian rhythm abnormalities (Da-
nel et al., 2003) may uncover nocturnal physiological effects
that were not measured in this pilot study.
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